An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease.
Mahmoud Ahmed EbadaAbdelmagid M ElmatbolyAhmed Said AliAhmed Mohamed IbrahimNotila FayedAhmed Faisal FaisalSouad AlkanjPublished in: International journal of colorectal disease (2019)
CT-P13 is effective and well tolerated in short and long-term periods. Switching to CT-P13 is recommended for the management of IBD.